ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,220.90
0.24%
S&P ASX All Technology
3,825.10
-0.11%
Brent Oil
73.285
0.00%
US Dollar vs AUD
1.60359
0.06%
Bitcoin
98,035.85
-0.65%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Sonnet BioTherapeutics Holdings Inc (SONN) Share Price

Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings Inc (SONN)

NASDAQ
1.42
-0.02
(-1.39%)
Closed 25 December 8:00AM
Delayed by 15 minutes
1.42
0.00
(0.00%)
After Hours: 7:59AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.42
Bid
1.42
Offer
1.45
Volume
64,682
1.41 Day's Range 1.50
1.42 52 Week Range 18.7192
Market Cap
923.444k
Previous Close
1.44
Open
1.43
Last Trade
94
@
1.43
Last Trade Time
Financial Volume
US$ 94,027
VWAP
1.4537
Average Volume (3m)
1,385,405
Shares Outstanding
650,313
Dividend Yield
-
PE Ratio
-0.05
Earnings Per Share (EPS)
-28.96
Revenue
148k
Net Profit
-18.83M

About Sonnet BioTherapeutics Holdings Inc

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Show more

Sector
Pharmaceutical Preparations
Industry
Management Consulting Svcs
Website
www.sonnetbio.com
Headquarters
Wilmington, Delaware, USA
Founded
2020
Sonnet BioTherapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SONN. The last closing price for Sonnet BioTherapeutics was US$1.44. Over the last year, Sonnet BioTherapeutics shares have traded in a share price range of US$ 1.42 to US$ 18.7192.

Sonnet BioTherapeutics currently has 650,313 shares in issue. The market capitalisation of Sonnet BioTherapeutics is US$936,450.72 . Sonnet BioTherapeutics has a price to earnings ratio (PE ratio) of -0.05.

Ask ADVFN Intelligence (AI)

SONN Latest News

More News

Form D - Notice of Exempt Offering of Securities

24 December 2024
Edgar (US Regulatory)

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...

24 December 2024
GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

18 December 2024
Edgar (US Regulatory)

Form 8-K - Current report

18 December 2024
Edgar (US Regulatory)

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)  Executed licensing agreement to support initiation of a...

18 December 2024
GlobeNewswire Inc.

Form 8-K - Current report

11 December 2024
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

11 December 2024
Edgar (US Regulatory)

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic...

10 December 2024
GlobeNewswire Inc.

Form 8-K - Current report

10 December 2024
Edgar (US Regulatory)

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months...

10 December 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.52-26.80412371131.941.941.422848961.58233896CS
4-1.34-48.55072463772.764.851.4229071291.97062976CS
12-4.69-76.7594108026.1110.021.4213854052.56526897CS
26-6.4096-81.86369674067.829610.021.427189532.93774701CS
52-12.34-89.680232558113.7618.71921.424017863.96774602CS
156-1132.02-99.87471767361133.441649.40161.421944577562.75444985CS
260-15324.66-99.990734747615326.0839916.81.4223246142550.04422433CS

SONN - Frequently Asked Questions (FAQ)

What is the current Sonnet BioTherapeutics share price?
The current share price of Sonnet BioTherapeutics is US$ 1.42
How many Sonnet BioTherapeutics shares are in issue?
Sonnet BioTherapeutics has 650,313 shares in issue
What is the market cap of Sonnet BioTherapeutics?
The market capitalisation of Sonnet BioTherapeutics is USD 936.45k
What is the 1 year trading range for Sonnet BioTherapeutics share price?
Sonnet BioTherapeutics has traded in the range of US$ 1.42 to US$ 18.7192 during the past year
What is the PE ratio of Sonnet BioTherapeutics?
The price to earnings ratio of Sonnet BioTherapeutics is -0.05
What is the cash to sales ratio of Sonnet BioTherapeutics?
The cash to sales ratio of Sonnet BioTherapeutics is 6.24
What is the reporting currency for Sonnet BioTherapeutics?
Sonnet BioTherapeutics reports financial results in USD
What is the latest annual turnover for Sonnet BioTherapeutics?
The latest annual turnover of Sonnet BioTherapeutics is USD 148k
What is the latest annual profit for Sonnet BioTherapeutics?
The latest annual profit of Sonnet BioTherapeutics is USD -18.83M
What is the registered address of Sonnet BioTherapeutics?
The registered address for Sonnet BioTherapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Sonnet BioTherapeutics website address?
The website address for Sonnet BioTherapeutics is www.sonnetbio.com
Which industry sector does Sonnet BioTherapeutics operate in?
Sonnet BioTherapeutics operates in the MANAGEMENT CONSULTING SVCS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
US$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
US$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
108.38M

SONN Discussion

View Posts
tw0122 tw0122 2 weeks ago
Cash out time 5.45 + 150%
👍 1
LowFloatLopes LowFloatLopes 2 weeks ago
I'm at $2.50 out at $4.50 in less than 8 mins lol 
👍️0
tw0122 tw0122 2 weeks ago
Don't stay in long this one hardly ever stays up high long 3.49 +'80%
👍️0
Monksdream Monksdream 2 weeks ago
SONN, 10Q due DEC 13
👍️0
tw0122 tw0122 2 months ago
Reverse split was September 
👍️0
Invest-in-America Invest-in-America 2 months ago
SONN: They announced a DUMP-to-Market routine!!! (The WORST thing any firm could do when their stock is SOARING!!!! WOW!!!!)
👍️0
Tiger Money Tiger Money 2 months ago
What is going on here?  Reverse?  Where is the float on this train wreck now?
👍️0
bigfart bigfart 2 months ago
So insiders can dump before the RS
👍️0
tw0122 tw0122 2 months ago
Reverse split offering and now some news $8s
👍️0
tw0122 tw0122 3 months ago
May the reverse split gods come soon. Keep an eye!
👍️0
BooDog BooDog 3 months ago
Another split here too.

https://www.globenewswire.com/news-release/2024/09/25/2952951/0/en/Sonnet-BioTherapeutics-Announces-1-for-8-Reverse-Stock-Split.html
👍️0
Clemdane Clemdane 4 months ago
Big jump today!
👍️0
Awl416 Awl416 4 months ago
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
👍️ 1
Monksdream Monksdream 4 months ago
SONN new 52=low
👍️0
Clemdane Clemdane 4 months ago
Big jump back up today. It's a very "risk on" stock so when the market is scared, everyone dumps it.
👍️0
Monksdream Monksdream 4 months ago
SONN new 52 week low
👍️0
Monksdream Monksdream 4 months ago
SONN new 52 week low
👍️0
Monksdream Monksdream 6 months ago
SONN new 52 week low
👍️0
Monksdream Monksdream 6 months ago
SONN new 52 week low
👍️0
BooDog BooDog 8 months ago
I see 76 followers here. And I have a target price of around 1.50 for support.

GL.

I do own shares and am looking for this to have a good future.
👍️0
maq1214 maq1214 9 months ago
Something must be happening behind closed doors. This stock has been ridiculously quite since the RS. Glad it’s greening again !
👍️0
81vette 81vette 9 months ago
23,198 watchers now,word is spreading like wildfire,somebody with lots of followers must be promoting this
👍️0
81vette 81vette 9 months ago
They are rare,not 1 in a million lotto rare but only a few per year maybe happen,the chart is great,how many bio pharma are bullish for 5 months straight (1 in a million lol) has accumulated also and that is very promising
👍️0
maq1214 maq1214 9 months ago
Do you think we are likely to see a merger/ partnership? I;m really hoping the reverse split last year cost me a lot
👍️0
81vette 81vette 9 months ago
$2.23 is 5 month high,next res. $5 mental,$7.57(sma200),big gaps to fill,mental 10/15/20/25 ect. lots of blue sky past 7.57,any kind of merger/buyout news could send it,thats the hype/hope/pump talk right now
👍️0
81vette 81vette 9 months ago
254k short,could squeeze with ZERO BORROW,73% fee(no rebate),5 months of accumulation= in the know are loading
👍️0
81vette 81vette 9 months ago
5 month uptrend(since r/s)accumulation,zero borrow,moving today on low vol(up13%),clinical trials different stages,float 2.78m,o/s 3m
👍️0
BooDog BooDog 9 months ago
Riding free again.
👍️0
Monksdream Monksdream 10 months ago
SONN under $2
👍️0
crowin crowin 10 months ago
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $30
👍️0
maq1214 maq1214 10 months ago
This should get exciting soon, crazy volume yesterday !
👍️0
BooDog BooDog 11 months ago
IS it just greed or might this make good for another round trip? We'll see next week.
👍️0
BooDog BooDog 12 months ago
Good move IMO. Surprising actually.

On December 27, 2023, the Compensation Committee (the “Committee”) of the Board of Directors of Sonnet BioTherapeutics Holdings, Inc. (the “Company”) cancelled accrued but unpaid bonuses (the “Cancelled Bonuses”) that had been awarded for fiscal years 2022 and 2023 by the Committee to certain executive officers and employees of the Company. The Cancelled Bonuses total $1,930,773.10 and include (i) $631,768.12 awarded to Pankaj Mohan, Ph.D., the Company’s President and Chief Executive Officer, (ii) $312,741.79 awarded to John Cini, Ph.D, the Company’s Chief Scientific Officer and (iii) $364,504.40 awarded to Jay Cross, the Company’s Chief Financial Officer.

https://ih.advfn.com/stock-market/NASDAQ/sonnet-biotherapeutics-SONN/stock-news/92897290/form-8-k-current-report
👍️0
Monksdream Monksdream 1 year ago
SONN new 52 week low
👍️0
BooDog BooDog 1 year ago
Discount. Maybe I should have added "again". 1.60 offering and this is pushing towards the $. Very small float. Just playing the bounce. IF there is one lol.

https://www.accesswire.com/viewarticle.aspx?id=796208
👍️0
valleybenedetto valleybenedetto 1 year ago
Absolute piece of shit co, shit stock, dilution is endless. CEO should be fired. Sell now
👍️0
Monksdream Monksdream 1 year ago
SONN new 52 week low
👍️0
Monksdream Monksdream 1 year ago
SONN new 52 week low
👍️0
Monksdream Monksdream 1 year ago
SONN new 52 week low
👍️0
Monksdream Monksdream 1 year ago
SONN new 52 week low
👍️0
valleybenedetto valleybenedetto 1 year ago
If they would stop shitting on shareholders, cut costs and actually get something accomplished that would be a start.
👍️0
Monksdream Monksdream 1 year ago
If the stock continues to make new lows on its way to a delisting to Cromwell Coulson’s stock market or a dissolution I will continue to record it
👍️0
valleybenedetto valleybenedetto 1 year ago
You worry about you ok?
👍️0
Monksdream Monksdream 1 year ago
You aren’t getting any money back
Time to move on
👍️0
valleybenedetto valleybenedetto 1 year ago
Not an Urban Myth ..I've already checked. They have current D and O insurance.
👍️0
Monksdream Monksdream 1 year ago
Oh goddamn tell me another urban myth
👍️0
valleybenedetto valleybenedetto 1 year ago
They have D and O insurance. That's where you collect from. That's directors and officers insurance if you didn't know
👍️0
Monksdream Monksdream 1 year ago
You wouldn’t get anything from a class action lawsuit
Anyone connected to professional asset management abandoned this company long ago
👍️0
valleybenedetto valleybenedetto 1 year ago
CEO is awful. Nothing but offerings and RS. No meaningful news in months. Class action suit might be in order here.
👍️0
Monksdream Monksdream 1 year ago
SONN new 52 week low
👍️0

Your Recent History

NASDAQ
SONN
Sonnet BioTherapeutics
TG
M1W
Goldquest Mining
AQSE
TSP
TruSpine Technologies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads